3月27日 - ** 胃肠道 (GI) 疾病为重点的生物制药公司Phathom Pharmaceuticals PHAT.O股价盘前上涨2%至11美元
** 巴克莱将该股评级从 "等权重 "上调至 "增持"
** 券商将目标价从16美元上调至18美元，较上一交易日收盘价上涨66.8%。
** "我们认为，强化的资产负债表、强有力的指导和重点突出的商业战略相结合，表明 11 美元的股价与基本面不符" --巴克莱银行
** 券商指出，更有针对性的 GI 方法似乎能推动更好的采用率
** 截至上次收盘，该股今年以来累计下跌 34.9%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.